Search Bar & Filters
Found 37 Actively Recruiting clinical trials
Actively Recruiting
This research aims to describe the characteristics of people with asthma, covering a wide range of disease severities. It studies sociodemographic and clinical features, treatment patterns, disease burden, biomarkers, and health-related quality of life. The study includes both a cross-sectional part and a prospective follow-up to observe changes in asthma over time. Participants are grouped based on their asthma treatments and disease control, including those receiving various doses of inhaled corticosteroids or biologic therapies as part of their usual care. The study has two main parts Part 1 assesses characteristics at baseline, while Part 2 follows participants for two years to evaluate changes in symptoms, lung function, treatment use, and biomarkers. During the study, participants will provide information through questionnaires and clinical assessments, including lung tests and blood samples. Researchers will collect both participant- and physician-reported outcomes to analyze asthma severity, control, quality of life, and healthcare use. The study extends up to two years, with evaluations at baseline and at weeks 52 and 104 to understand disease progression and treatment patterns.
Actively Recruiting
Researchers are studying chronic migraine, a condition causing moderate to severe headaches often on one side of the head, sometimes with nausea, vomiting, and sensitivity to light or sound. This trial evaluates how well the medicine atogepant works compared to a placebo in preventing chronic migraine in participants aged 12 to 17 years. The study also monitors adverse events to assess safety. Participants will be randomly assigned to receive either oral atogepant tablets or placebo once daily for 12 weeks. This double-blind study means neither the participants nor the doctors know who receives the medicine or placebo. Following the treatment, participants will be observed for an additional 4 weeks. During the study, participants will visit hospitals or clinics regularly for assessments. They will complete daily diaries, undergo medical evaluations, blood tests, side effect checks, and questionnaires. The main outcomes include tracking adverse events and changes in monthly migraine days, along with measures of headache days, medication use, and quality of life over approximately 16 weeks.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of atogepant, a medication currently approved for adults, in treating episodic migraine in children aged 6 to 17 years. The study focuses on pediatric participants who experience moderate to severe migraines with symptoms such as throbbing head pain, nausea, and sensitivity to light and sound. Limited treatment options exist for this age group, so the trial investigates different doses of atogepant to address this need. Participants are divided into groups based on age and receive either a placebo or low or high doses of atogepant tablets once daily for 12 weeks. Children aged 6 to 11 first undergo an open-label pharmacokinetic substudy to determine the appropriate dose before the double-blind treatment period. After the initial 12 weeks, participants either have a follow-up visit 4 weeks after their last dose or can continue receiving atogepant for an additional 52 weeks in an extension study. Throughout the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor the effects of treatment and check for side effects. The main outcomes measured include changes in monthly migraine days and safety through adverse event tracking. The study plans to enroll about 450 children worldwide, with comprehensive monitoring over the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.
Actively Recruiting
Researchers are evaluating ibuzatrelvir to determine its effectiveness and safety in treating adults and adolescents aged 12 and older who have COVID-19 but are not hospitalized. The study focuses on individuals at high risk of progressing to severe illness. Participants will be randomly assigned to receive either ibuzatrelvir or a placebo, alongside standard care as available locally, with the study lasting approximately six months. Participants will receive either ibuzatrelvir tablets or placebo tablets orally every 12 hours for five days. This is a randomized, double-blind, phase 3 study comparing the investigational drug to placebo. The study allows co-administration of locally available standard treatments. The treatment period is followed by monitoring to assess outcomes related to COVID-19 progression and symptom resolution. During the study, participants will be observed for emergency department visits, hospitalizations, mortality, symptom resolution, and viral load changes over 28 days and up to 24 weeks. Researchers will collect data on medical events, including cardiovascular, renal, and pulmonary complications, as well as Long COVID symptoms. Safety is monitored through adverse event tracking. Overall participation lasts about six months with multiple assessments during this time.
Actively Recruiting
Researchers are evaluating the use of rimegepant, a medication that blocks calcitonin gene-related peptide CGRP receptors, for the preventive treatment of chronic migraine in adults. The study focuses on whether taking rimegepant once daily can reduce the number of migraine days compared to a placebo. This Phase 3 study involves approximately 400 adults aged 18 years or older who have had chronic migraine for at least one year. Participants first complete a 28-day observation period without any study treatment. Then, they are randomly assigned to receive either rimegepant 75 mg orally disintegrating tablets or a matching placebo once daily for 12 weeks in a double-blind phase. Those who finish this phase and remain eligible enter a 12-week open-label extension where all receive rimegepant 75 mg daily. During this extension, participants may take up to 10 additional doses of rimegepant monthly to treat breakthrough migraine attacks. The study concludes with a 28-day follow-up period. Throughout the trial, participants record migraine and headache details using an electronic diary and undergo regular assessments including laboratory tests, vital signs, and electrocardiograms. Researchers measure changes in monthly migraine days and other outcomes such as headache severity, medication use, quality of life, work productivity, and cognitive function. Safety and tolerability of daily rimegepant use are closely monitored, and the total study duration is about 32 weeks.
Actively Recruiting
Phase 3 Study of Rimegepant for Intermittent Prevention of Menstrual Migraine in Women Aged 18 to 45
Researchers are evaluating the use of rimegepant for intermittent prevention of menstrual migraine in women aged 18 to 45 who experience migraine attacks related to their menstrual cycle. This Phase 3, double-blind, randomized study compares rimegepant with placebo to assess its efficacy and safety during the peri-menstrual period. The study focuses on migraine frequency and severity in women with a history of menstrual migraine and regular menstrual cycles. Participants receive either rimegepant 75 mg orally disintegrating tablets for 7 days during each peri-menstrual period or a matching placebo, along with standard care for acute migraine treatment as needed. The study treatment cycles are repeated over 5 menstrual cycles in the double-blind treatment phase. The study also includes an acute treatment dosing option with rimegepant as needed. During the study, participants will be monitored for changes in the number of migraine and headache days, use of migraine medications, and functional disability related to migraine. Cognitive function is also assessed. Researchers will conduct evaluations over 5 months, covering 5 menstrual cycles, and measure outcomes related to migraine frequency and severity during the peri-menstrual period. Safety and tolerability will be closely monitored throughout the study.
Actively Recruiting
Researchers are evaluating how well active surveillance helps doctors monitor patients with low-risk germ cell tumors after tumor removal. The trial also compares two chemotherapy regimenscarboplatin-based and cisplatin-basedin treating pediatric, adolescent, and young adult patients with standard risk germ cell tumors. This phase III study aims to maintain high survival rates and assess event-free survival, hearing outcomes, body composition effects, and tumor marker correlations. The study includes patients with low-risk stage I germ cell tumors who undergo observation and may transfer to standard risk treatment arms if the tumor recurs. Participants with standard risk non-seminomatous germ cell tumors are randomly assigned to one of four chemotherapy regimens involving bleomycin, etoposide, carboplatin, or cisplatin. Treatments are given intravenously in cycles every 21 days, with up to 3 or 4 cycles depending on the arm and risk group. Throughout the trial, patients undergo imaging scans, blood sample collections, tumor biopsies, and pulmonary function tests to monitor response and side effects. Participants are followed for up to 10 years after treatment completion, with regular visits every 2 months for the first year, then every 3 to 6 months for the next two years, and less frequently thereafter. The study tracks overall survival, event-free survival, hearing loss, patient-reported hearing outcomes, lean body mass, and tumor marker declines. Safety is monitored with tests including audiometry and pulmonary function, and patient questionnaires assess effects such as tinnitus and neuropathy. This long-term follow-up helps evaluate treatment impact and late effects.
Actively Recruiting
Researchers are evaluating the use of olaparib, a PARP inhibitor, as a maintenance treatment following surgery and chemotherapy in patients with pancreatic cancer that has been surgically removed and who have a pathogenic mutation in BRCA1, BRCA2, or PALB2. This phase II randomized trial aims to determine if adding olaparib improves relapse-free survival compared to placebo. The study also explores overall survival and treatment effects based on genetic mutation types and prior chemotherapy regimens. Participants are randomly assigned to receive either olaparib or a placebo taken orally twice daily in 28-day cycles for up to 12 cycles, provided there is no disease progression or unacceptable side effects. Throughout the study, patients undergo CT or MRI scans and have blood samples collected regularly. After completing treatment, patients are followed for up to 10 years with scheduled visits at 30 days post-treatment, every 4 months during the first year, and every 6 months for years 2 through 10. During the trial, participants are closely monitored through imaging and blood tests to assess disease recurrence and overall survival. The primary outcome measures relapse-free survival from randomization up to 44 months, while secondary outcomes include long-term survival and comparisons of treatment effects based on mutation type and chemotherapy received. Safety and disease status are assessed regularly to track treatment impact and progression over an extended follow-up period.
Actively Recruiting
Researchers are evaluating the use of carboplatin chemotherapy given before surgery in patients with high-risk prostate cancer who have inherited mutations in the BRCA1 or BRCA2 genes. This phase II trial aims to determine how well carboplatin works in shrinking tumors prior to surgery and to assess its impact on disease progression and survival. The study also monitors treatment side effects and collects tissue samples for future research. Participants receive carboplatin intravenously before undergoing prostate surgery. Those who show signs of disease progression after surgery will have imaging tests such as CT, MRI, chest X-ray, or PSMA PET scans. Blood samples are collected throughout the trial to monitor health and support additional studies. The study includes detailed follow-up to evaluate treatment outcomes and safety. During the trial, participants will have regular assessments including physical exams, PSA tests, and imaging scans if needed. Researchers will review the rate of complete tumor response after carboplatin treatment at surgery and track progression-free survival and overall survival over time. Safety and side effects of the treatment are closely monitored. Participation may last up to five years with ongoing collection of health data and specimens.
1-10 of 37
1